ImmunityBio presents new comparison results on Anktiva, TAR-200

ImmunityBio (IBRX) announced it will present new treatment comparison results evaluating Anktiva plus Bacillus Calmette-Guerin versus nadofaragene firadenovec-vncg and TAR-200 in patients with non-muscle invasive bladder cancer carcinoma in situ, with or without papillary disease, at the American Urological Association Annual Meeting in Washington, DC, May 15-18. An additional oral presentation will include new insights into research of intravesical recombinant BCG in BCG-naive patients. These analyses are clinically relevant for urologists managing an increasingly complex NMIBC treatment landscape, particularly among patients with BCG-unresponsive disease. In the context of limited direct comparative data, cross-trial analyses may provide important context to inform treatment selection and sequencing. By evaluating Anktiva + BCG relative to other available options, these data may help characterize comparative efficacy and durability of response within current treatment paradigms.